Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
|Videos|February 14, 2014
Pazopanib for the Treatment of Soft Tissue Sarcoma
Author(s)Vicki Keedy, MD
Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses pazopanib for the treatment of soft tissue sarcoma.
Advertisement
Clinical Pearls
Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses pazopanib for the treatment of soft tissue sarcoma.
- Pazopanib was recently approved for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy
- Treatment with pazopanib quadrupled progression-free survival compared with placebo
- Drugs to treat soft tissue sarcoma are generally toxic
- Pazopanib is well tolerated, with some instances of extended fatigue
Advertisement
Related to this article
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
LRRC15-targeting ADC SOT106 gains FDA fast track and orphan status for sarcomas, showing preclinical promise as it heads into a first-in-human trial.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
Denosumab Biosimilar Approved For Existing Oncology Indications
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5